Keywords: UK, NICE, Draft guidance, Erbitux, Avastin, Vectibix, Merck KGaA, Roche, Amgen

UK’s NICE negative draft guidance for metastatic colorectal cancer drugs Erbitux, Avastin and Vectibix

Article | 06 September 2011

Print This

In new draft guidance issued this week, UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) says ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in